Relates to the dispensing of certain prescriptions
Impact
The proposed amendments would simplify the dispensing process for mifepristone and misoprostol while maintaining necessary prescription records. A key aspect of the bill mandates that any entity dispensing these medications must keep a log with critical details, including prescription numbers and the names of both the dispenser and patient. This log must be maintained for at least five years. By altering the requirements around prescription labels, the bill could have significant implications for pharmacy practices and patient privacy in the context of reproductive health.
Summary
Bill A10428 seeks to amend existing education law regarding the dispensing of certain prescriptions, specifically mifepristone and misoprostol. Under this bill, prescriptions for these medications can be dispensed without including the name and address of the dispenser and patient on the prescription label. Instead, the label would need to include a prescription number or another identifying means. The intention behind this change is likely to enhance the confidentiality of individuals receiving these medications, potentially addressing privacy concerns raised by patients and healthcare providers.
Contention
While the bill aims to enhance patient privacy, it may also raise concerns among some stakeholders regarding the implications for oversight and monitoring of medication dispensing. Critics may argue that changes to labeling requirements could complicate tracking and accountability in cases where these medications could be misused. As such, the bill may stimulate debate around balancing patient confidentiality with public health safety and regulatory compliance in the pharmaceutical sector.
Same As
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.
Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.
Provides that the prescription label for medication abortion prescription drugs shall include the name of the dispensing health care practice instead of the name of the dispenser.
Provides that the prescription label for medication abortion prescription drugs shall include the name of the dispensing health care practice instead of the name of the dispenser.
Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.
Provides that the prescribing, dispensing, or receipt of mifepristone or any drug used for medication abortion shall not be considered a criminal conversion act under certain circumstances; provides that mifepristone or any drug used for medication abortion shall not be deemed to be adulterated or misbranded under certain circumstances.
Provides that the prescribing, dispensing, or receipt of mifepristone or any drug used for medication abortion shall not be considered a criminal conversion act under certain circumstances; provides that mifepristone or any drug used for medication abortion shall not be deemed to be adulterated or misbranded under certain circumstances.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.